Unbiased AI-powered news
The Navy awarded TOTE Services LLC a $2.2 billion contract to manage construction of up to eight Medium Landing Ships. The first vessel is scheduled for delivery in fall 2029.
en.antaranews.comThe Navy awarded TOTE Services LLC a $2.2 billion Vessel Construction Management contract this week. The Jacksonville, Florida-based company will oversee construction of the service's new Medium Landing Ships. The Marine Corps commissioned the ships for potential operations in the Indo-Pacific.
Each vessel measures about 100 meters and is designed to transport troops, equipment, and supplies between islands. The approach aims to accelerate construction by applying commercial shipbuilding practices.
Services will manage subcontracts with Bollinger Shipyards for one vessel and Fincantieri Marinette Marine for four vessels. The company will determine the award strategy for the remaining three ships, the Navy stated in a Monday press release. Construction is scheduled to begin later this year.
The first ship is set for delivery in fall 2029. The Navy previously selected Dutch shipbuilder Damen Naval to design the Landing Ship Transport 100. The design provides a 3,400-nautical-mile range and can deliver over 800 tons of cargo. The Nigerian Navy operates the design, and the Australian Navy selected it in 2024.
"We're taking a proven design and leveraging congressional authorities to move with urgency and approach shipbuilding differently," a Navy official said in the Monday press release.
These outlets didn't split into competing frames — coverage was uniform.
A 26-year-old Colombian national was fatally shot in Biddeford on Monday. The incident prompted federal officials to suspend most vehicle stops nationwide after two recent deaths.
Retired pilot Chesley Sullenberger said on July 14, 2026, that he has early-stage Alzheimer’s disease. He described initial symptoms and expressed resolve to face the condition with his family.
Japan TimesThe University of Oxford has started an early-stage clinical trial of a vaccine targeting the Bundibugyo strain of Ebola. The trial will enroll 50 healthy adults to test safety and immune response.